Will Morton

ASTRO: Ultra-low-dose RT controls myeloma bone pain

The pain response rate was 59% at four weeks.

September 27, 2026

What are the effects of COVID-19 pneumonia after 5 years?

After five years, residual lesions persisted in 35.6% of survivors (37 of 104).

September 24, 2026

Representative longitudinal chest CT images and five-year parametric response mapping (PRM), pulmonary vascular CT reconstructions, and hyperpolarized xenon-129 (Xe-129) ventilation MRI scans from survivors of nonsevere and severe COVID-19 pneumonia. (A–F) Images in a 68-year-old male survivor of nonsevere COVID-19 pneumonia, (G–L) 62-year-old male survivor of severe COVID-19 pneumonia, and (M–R) 55-year-old male survivor of severe COVID-19 pneumonia. For each participant, the first three columns show coronal chest CT images from the acute phase (A, G, M), two-year follow-up (B, H, N), and five-year follow-up (C, I, O) (left to right). The fourth column (D, J, P) shows a coronal PRM image for each participant at five-year follow-up derived from paired inspiratory and expiratory CT scans, showing the spatial distribution of lung functional categories. Green indicates normal lung tissue, yellow indicates functional small airway disease, and red indicates emphysema. The second-to-last column shows volume-rendered small pulmonary vessel visualization (red) at five-year follow-up per participant (E, K, Q). The column on the far right (F, L, R) shows a hyperpolarized Xe-129 MRI ventilation defect percentage (VDP) map at five-year follow-up per participant. Dark blue represents high Xe-129 signal intensity, corresponding to well-ventilated lung regions, whereas red represents no Xe-129 signal intensity, corresponding to ventilation defects. At five-year follow-up, the 68-year-old survivor of nonsevere COVID-19 pneumonia (top row) showed near-complete radiologic resolution, no respiratory symptoms, and preserved pulmonary function. In contrast, the 62-year-old survivor of severe COVID-19 pneumonia (middle row) showed persistent fibrotic linear opacities without respiratory symptoms and mildly reduced pulmonary function. The 55-year-old survivor of severe COVID-19 pneumonia (bottom row) showed persistent scattered fibrotic linear opacities and focal emphysematous changes in both lungs, with dyspnea and impaired gas exchange function. The VDP values obtained from F, L, and R were 7.7%, 7.1%, and 6.3%, respectively.

X-rays reveal severe aortic calcification in dialysis patients

The findings reinforce lateral lumbar radiography's potential as an accessible, low-cost tool for opportunistic cardiovascular risk stratification in dialysis care.

September 22, 2026

UAE provides long-term benefits in women with uterine fibroids

Of 175 survey respondents, 132 reported significant symptom improvement at least two years following embolization.

September 3, 2026

Molecular Imaging

PET outperforms CT in ovarian cancer

Peritoneal carcinomatosis in ovarian cancer is cancer that has spread from the ovaries to the peritoneum.

August 28, 2026

Comparison of contrast-enhanced CT (ceCT) and FAPI-PET in detecting peritoneal carcinomatosis in patient with advanced ovarian carcinoma. (A) ceCT shows subtle peritoneal thickening that is difficult to delineate. (B) Maximum-intensity-projection image demonstrating diffuse intense FAPI uptake corresponding to extensive peritoneal carcinomatosis. (C) FAPI-PET shows intense uptake corresponding with peritoneal carcinomatosis, with improved lesion conspicuity over ceCT.

Molecular Imaging

FAPI-PET/CT shows promise in hepatopancreatobiliary cancers

FAPI-PET/CT could potentially improve noninvasive cancer staging, and, ultimately, clinical decision making.

August 13, 2026

Shown is a 69-year-old man with a cholangiocarcinoma in the distal common bile duct. F-18 FDG-PET/CT was negative where Ga-68 FAPI-46 PET/CT showed high focal FAPI uptake in the liver hilum and surrounding lymph nodes. a-d: F-18 FDG-PET/CT, e-h: Ga-68 FAPI-46 PET/CT. a, b, e, f: Maximum intensity projections, c, g: axial fusion images, d, h: non-contrast enhanced CT.

Radiation Oncology/Therapy

SBRT for prostate cancer cuts side effects, falls short on disease control

A multinational team evaluated SBRT against moderately hypofractionated intensity-modulated radiation therapy in a phase III trial.

August 13, 2026

Prostate Imaging

Molecular Imaging

PET/CT predicts response to neoadjuvant therapy in breast cancer

Monitoring neoadjuvant therapy response in HER2-positive breast cancer is challenging with existing tools.

August 11, 2026

Ga-68 HER2-PET/CT images before neoadjuvant therapy, at end of second cycle, and before surgery. (A) Baseline scan demonstrated soft-tissue lesion measuring approximately 2.3 × 2.2 cm in upper outer quadrant of left breast, with marked radiotracer uptake and SUVmax of 10.1. (B) At end of second cycle, imaging revealed residual lesion of approximately 2.2 × 1.0 cm in same region, without abnormal radiotracer accumulation. (C) Preoperative imaging demonstrated further reduction in lesion size to approximately 2.0 × 0.6 cm, with no abnormal tracer uptake detected.

VLMs miss most lung nodules on chest x-rays

Findings indicate poor performance of six VLMs for lung nodule detection on chest x-rays.

August 6, 2026

TACE plus thermal ablation improves survival in liver cancer

Median progression-free survival was 17.7 months with TACE-ablation versus 7.3 months with TACE alone.

July 30, 2026

Page 1 of 5

Knee Joint Pain 400

ASTRO: Low-dose RT tied to fewer knee replacements

Patients who underwent low-dose RT had longer symptom relief, less joint deterioration, and lower disability risk.

Astro1

ASTRO: Ultra-low-dose RT controls myeloma bone pain

Thomas DeLaney, MD, delivered a talk at ASTRO September 27 on preserving limbs in patients with extremity sarcoma.

ASTRO: Limb-sparing care now standard for extremity sarcoma

Siemens Healthineers' Accela radiotherapy system

ASTRO: Siemens unveils Accela radiotherapy system

Free webinar for radiology leaders

Free webinar for radiology leaders

ASTRO: Low-dose RT tied to fewer knee replacements

By Amerigo Allegretto

Patients who underwent low-dose RT had longer symptom relief, less joint deterioration, and lower disability risk.

September 27, 2026

Knee Joint Pain 400

ASTRO: Ultra-low-dose RT controls myeloma bone pain

The pain response rate was 59% at four weeks.

September 27, 2026

ASTRO: Limb-sparing care now standard for extremity sarcoma

In the 1970s, over 50% of extremity soft tissue sarcomas were treated by amputation.

September 27, 2026

Thomas DeLaney, MD, delivered a talk at ASTRO September 27 on preserving limbs in patients with extremity sarcoma.

ASTRO: Siemens unveils Accela radiotherapy system

By AuntMinnie.com staff writers

NeoArc allows stereotactic treatment to be delivered within a single breath hold.

September 27, 2026

Siemens Healthineers' Accela radiotherapy system

ASTRO: Proton RT controls high-risk neuroblastoma

Findings support PRT as a strategy to reduce long-term morbidity without compromising oncologic outcomes.

September 26, 2026

Astro 2026 Thumb 2

ASTRO: How does tumor location affect survival in patients with esophageal cancer?

Upper esophageal tumors were associated with the best survival, while middle esophageal location carried significantly worse odds.

September 26, 2026

Astro 2026 Thumb

CT-based AI model predicts pneumonitis in lung cancer patients

By Amerigo Allegretto

The algorithm outperformed clinical and radiomics models in these patients.

September 25, 2026

CIPHER, an AI-powered CT foundation model, identifies patients with lung cancer at increased risk of immunotherapy-induced pneumonitis before treatment begins. The AI-generated output, shown here, highlights lung abnormalities to support early risk assessment and personalized patient care.

Women's Imaging MinnieCast, Episode 18: On the road with the LBCA

By Amerigo Allegretto

The Lobular Breast Cancer Alliance (LBCA) is embarking on a nationwide bus tour to raise disease awareness.

September 25, 2026

Minnie Cast Thumbnail (26)

What are the effects of COVID-19 pneumonia after 5 years?

After five years, residual lesions persisted in 35.6% of survivors (37 of 104).

September 24, 2026

Representative longitudinal chest CT images and five-year parametric response mapping (PRM), pulmonary vascular CT reconstructions, and hyperpolarized xenon-129 (Xe-129) ventilation MRI scans from survivors of nonsevere and severe COVID-19 pneumonia. (A–F) Images in a 68-year-old male survivor of nonsevere COVID-19 pneumonia, (G–L) 62-year-old male survivor of severe COVID-19 pneumonia, and (M–R) 55-year-old male survivor of severe COVID-19 pneumonia. For each participant, the first three columns show coronal chest CT images from the acute phase (A, G, M), two-year follow-up (B, H, N), and five-year follow-up (C, I, O) (left to right). The fourth column (D, J, P) shows a coronal PRM image for each participant at five-year follow-up derived from paired inspiratory and expiratory CT scans, showing the spatial distribution of lung functional categories. Green indicates normal lung tissue, yellow indicates functional small airway disease, and red indicates emphysema. The second-to-last column shows volume-rendered small pulmonary vessel visualization (red) at five-year follow-up per participant (E, K, Q). The column on the far right (F, L, R) shows a hyperpolarized Xe-129 MRI ventilation defect percentage (VDP) map at five-year follow-up per participant. Dark blue represents high Xe-129 signal intensity, corresponding to well-ventilated lung regions, whereas red represents no Xe-129 signal intensity, corresponding to ventilation defects. At five-year follow-up, the 68-year-old survivor of nonsevere COVID-19 pneumonia (top row) showed near-complete radiologic resolution, no respiratory symptoms, and preserved pulmonary function. In contrast, the 62-year-old survivor of severe COVID-19 pneumonia (middle row) showed persistent fibrotic linear opacities without respiratory symptoms and mildly reduced pulmonary function. The 55-year-old survivor of severe COVID-19 pneumonia (bottom row) showed persistent scattered fibrotic linear opacities and focal emphysematous changes in both lungs, with dyspnea and impaired gas exchange function. The VDP values obtained from F, L, and R were 7.7%, 7.1%, and 6.3%, respectively.

USC researchers develop “plug-and-play" platform for PET tracers

Preliminary work suggests the approach can generate tracers targeting fibroblast activation protein.

September 24, 2026

Nuclear Medicine

Image-based grading system estimates nasopharyngeal carcinoma severity

By Amerigo Allegretto

The four-tier grading system showed excellent reliability and good prognostic value for patients with nasopharyngeal carcinoma.

September 23, 2026

Representative MRI scans for which the independently assigned imaging-derived extranodal extension (iENE) grades differed among the readers. (A) Axial and sagittal images in a 56-year-old male patient with nasopharyngeal carcinoma and cervical nodal metastases. Readers 1 and 3 interpreted the finding as a metastatic lymph node invading the left sternocleidomastoid muscle (arrow) and assessed an iENE grade of 3, whereas reader 2 assigned a grade of 2. After joint review, the radiologists reached a consensus on the absence of definite sternocleidomastoid muscle invasion, and the final iENE grade was 2. (B) Axial and sagittal images in a 52-year-old male patient with nasopharyngeal carcinoma and cervical nodal metastases. Reader 1 interpreted the findings as a single enlarged metastatic lymph node and assessed an iENE grade of 1, whereas readers 2 and 3 interpreted them as two coalescent metastatic lymph nodes (arrows) and assessed a grade of 2. After joint review, the radiologists reached a consensus on the coalescence of the two metastatic lymph nodes, and the final iENE grade was 2.

ASTRO 2026 to center on translating radiotherapy data into dialogue

Radiopharmaceutical therapy will feature in a dedicated hands-on workshop alongside a roundtable.

September 23, 2026

Page 1 of 252